Taysha Gene Therapies, Inc.
TSHA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 39.80 | -0.50 | -0.64 | 0.27 |
| FCF Yield | -2.10% | -2.93% | -5.98% | -4.23% |
| EV / EBITDA | -21.32 | -13.02 | -12.75 | -16.31 |
| Quality | ||||
| ROIC | -11.82% | -8.58% | -17.88% | -14.41% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.74 | 0.75 | 1.02 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | -23.96% | -5.52% | 0.07% | 49.34% |
| Free Cash Flow Growth | -20.26% | 9.88% | -22.35% | 15.45% |
| Safety | ||||
| Net Debt / EBITDA | 8.25 | 9.52 | 2.60 | 4.11 |
| Interest Coverage | 2,268.27 | -1,573.71 | -1,127.42 | -906.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |